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Background
Cutaneous lupus erythematosus (CLE) is an autoimmune dis-
ease with heterogeneous clinical features that can be divided
in acute (ACLE), subacute (SCLE), and chronic (CCLE) [1].
This classification is based on a combination of clinical
features, histological changes, laboratory abnormalities, and
average duration of skin lesions [2].
CCLE is the most prevalent form of CLE [1], including
several subtypes. Discoid lupus erythematosus (DLE) is
the most common form of CCLE, generally involving
the face (forehead, philtrum, malar region, nose, ears,
and cheek) in a longstanding and disfiguring way [3].
DLE involving the eyelids is rare and it may precede the
development of DLE in other skin locations [4, 5]. Blepharitis
and infiltrated erythematous plaques, with skin atrophy, scar-
ring, and telangiectasia are most frequently observed [3, 4].
The lower eyelid is also commonly affected, usually with loss
of eyelashes (madarosis) [3].
Standard medical therapies include patient education on
proper sun protection along with topical corticosteroids or oral
antimalarial drugs. Topical tacrolimus and pimecrolimus have
also described as effective [3, 4]. If lack of response occurs,
other systemic immunosuppressive drugs may be tried [6].
Lasers have been described as successful in treating differ-
ent types of CLE, mostly DLE. Henderson et al. reported a
case using CO2 laser in 1986 [7] and Zachariae firstly used
argon laser to treat DLE telangiectasias [8]. The use of pulsed
dye laser (PDL) to treat DLE was described in 1995 by Núñez
et al. [9]; since then, it has been used in several forms of CLE
with clearance rates higher than 60% [9–14].
PDL improves the telangiectasic component, erythema,
and scaling. Histologic examination comparing before and
after PDL treatment shows reduction in the dermal lympho-
cytic infiltrate, more evident in the superficial papillary dermis
and improvement in basal cell hydropic degeneration and
pigment incontinence. A reduction of the expression of
cutaneous inflammatory regulators such as intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) was also observed [10]. Cosmetically satisfactory
results with few side effects (transient hipo/hyperpigmentation
and slight scarring) are reported in most cases [9, 11–13, 15, 16]
and recurrence after laser treatment is rare (3 of 14 patients with a
median of 10 months follow-up) [13].
The authors report a series of three cases, wishing to dis-
cuss the efficacy and safety of 595-nm PDL for the treatment
of DLE of the eyelids.
Material and methods
Three female patients with at least one lesion of DLE located
on the eyelids were treated with PDL (Table 1). All patients
gave their informed consent prior to their inclusion in the
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study. Clinical diagnosis was supported by histology and
direct immunofluorescence. Two of the patients had lesions
only on the eyelids and one had a long history of refractory
DLE involving her face and hands. All patients lacked
clinical response to previous treatments and were recom-
mended strict sun avoidance, use of sunglasses and topical
sunscreens (SPF 50). Patient 1 was maintained on systemic
therapy until the day of the laser treatment.
Fig. 1 Images before treatment
(left side) and 4 weeks after first
treatment (right side). a, b Refers
to patient 1. c, d Refers to patient
2. e, f Refers to patient 3
Table 2 Eyelid cutaneous lupus
erythematosus severity score Evaluation of active disease Scaling Absent (0); scale (1); verrucous, hypertrophic (2)
Erythema Absent (0); pink, faint erythema (1); red (2); dark red,
purple, violaceous, crusted, hemorrhagic (3)
Edema Absent (0); present (1)
Telangiectasias Absent (0); present (1)
Evaluation of damage Dyspigmentation Absent (0); present (1)
Madarosis Absent (0); present (1)
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The patients were treated with 595-nm PDL irradiation
(Cynergy, Cynosure,Massachusetts, USA) using a 10mm spot,
a fluency of 8 J/cm2, and a single pulse of 0.5 ms. Air cooling
system was set at level 4 (Cryo 6, Zimmer Medizinsysteme
GmbH, Neu-Ulm, Germany) and the lesions were covered with
a thin layer of ultrasound gel for epidermal protection. The eyes
were protected with an intra-ocular non reflective metal shield
(Cox II, Oculo-Plastik, Canada) and the laser was pointed away
from the eyeballs. The lesions were treated until a purpuric end
point was reached; this occasionally required double passing
but pulse stacking was avoided.
Clinical improvement was assessed by comparing digital
photographs of each patient taken at baseline and 4 weeks
after PDL, using a specific eyelid score (Table 2), adapted
from CLE Disease Area and Severity Index (CLASI) [17].
Six different parameters were evaluated: scaling, erythema,
edema, telangiectasias (these four corresponding to disease
activity), dyspigmentation, and madarosis (these two corre-
sponding to damage).
Results
The results are shown in Table 1. The treatment was well
tolerated with no need for anesthesia or analgesia. An intense
purpuric response was immediately observed after PDL treat-
ment. All the lesions responded to the treatment (Fig. 1), with
significant improvement of erythema, scaling, edema, and tel-
angiectasias. Madarosis was irreversible in all cases. One pa-
tient had a partial response and was retreated using the same
parameters with complete resolution of the lesions. No skin or
ocular side effects were reported.
Discussion
All the patients had DLE lesions on the left inferior eyelid, two
of them with madarosis. In all cases, PDL was used as an
alternative therapy in refractory lesions. One patient had been
taking hydroxychloroquine for 7 months with no response
until the day of laser therapy; given the rapid resolution of
the lesions after PDL therapy, we assume that the laser treat-
ment was the preponderant factor that leads to clinical im-
provement. One patient had a partial response and was
retreated with the same parameters at week 4, with complete
resolution of the lesions at week [8]. After laser treatment, the
patients were recommended strict sun avoidance, use of sun-
glasses, and topical sunscreens (SPF 50). There was no relapse
at 6 months follow-up.
Untreated eyelid DLE often leads to scarring, ectropion,
and madarosis. We highlight the good clinical response re-
garding the erythematosus and the telangiectasic component
and the lack of effect on the madarosis. Given the rapid
improvement after 1 or 2 sessions, we believe that PDL is a
valid treatment for active eyelid DLE and it should be offered
in an early phase of disease, in order to avoid irreversible
damage. Further studies are needed to support this hypothesis.
Ocular complications such as anisocoria, uveitis, pupillary
distortion, posterior synechiae, iris atrophy, nuclear cataract,
visual field defect, macular hole, and retinal scarring have
been reported with Diode laser (800 nm), Alexandrite laser
(755 nm), and Intense Pulsed Light (IPL) (500–1200 nm),
mostly related to lack of eye protection [18–21]. Although
PDL has a lower tissue penetration (wavelength of 595 nm),
permanent visual impairment has also been reported [22].
Eye safety procedures should always be followed during
periocular laser treatments. The treatment was well tolerated
without no anesthesia or analgesia.
Limitations of this study include the limited number of
treated patients and the short follow-up period.
Conclusions
PDL is safe and effective in treating DLE involving the
eyelids. Given the significant clinical improvement in this
study and the previously published good results of PDL in
the treatment of CLE [7, 9–14, 23], we recommend early
PDL treatment as an adjunctive therapy in controlling
DLE disease activity.
Compliance with ethical standards
Conflict of interest The authors declare that they have no conflicts of
interest.
References
1. DurosaroO, DavisMDP, Reed KB, Rohlinger AL (2009) Incidence
of cutaneous lupus erythematosus, 1965–2005: a population-based
study. Arch Dermatol 145(3):249–253
2. Okon LG, Werth VP (2014) Cutaneous lupus erythematosus: diag-
nosis and treatment. Best Pract Res Clin Rheumatol 27(3):391–404
3. Arrico L, Abbouda A, Abicca I, Malagola R (2015) Ocular
complications in cutaneous lupus erythematosus: a systematic
review with a meta-analysis of reported cases. J Ophthalmol
2015(254260):1–8
4. Cyran S, Douglass MC, Silverstein JL (1992) Chronic cutaneous
lupus erythematosus presenting as periorbital edema and erythema.
J Am Acad Dermatol 26(2):334–338
5. Aslam F, Lu L (2013) An unusual eyelid swelling. Q J Med
106(12):1145
6. Yélamos O, Roé E, Baselga E, Puig L (2014) Pediatric cutaneous
lupus erythematosus treated with pulsed dye laser. Pediatr Dermatol
31(1):113–115
7. Henderson DL, Odom JC (1986) Laser treatment of discoid lupus
(case report). Lasers Surg Med 6:12–15
Lasers Med Sci
8. Zachariae H, Bjerring P, Cramers M (1988) Argon laser treatment
of cutaneous vascular lesions in connective tissue diseases. Acta
Derm Venereol 68(2):179–182
9. Núnez M, Boixeda P, Miralles ES, de Misa RF, Ledo A (1995)
Pulsed dye laser treatment in lupus erythematosus telangiectoides.
Br J Dermatol 133:1010–1018
10. Díez MTT, Boixeda P, Moreno C, González JA, Zamorano ML,
Olasolo PJ (2011) Histopathology and immunohistochemistry of
cutaneous lupus erythematosus after pulsed dye laser treatment.
Dermatol Surg 37(7):971–981
11. Núnes M, Boixeda P, Miralles ES, de Misa RF, Ledo A (1996)
Pulsed dye laser treatment of telangiectatic chronic erythema of
cutaneous lupus erythematosus. Arch Dermatol 132:354–355
12. Gupta G, Roberts T (1999) Pulse dye laser treatment of subacute
cutaneous lupus erythematosus. Clin Exp Dermatol 24:498–500
13. Baniandrés O, Boixeda P, Belmar P, Pérez A (2003) Treatment of
lupus erythematosus with pulsed dye laser. Lasers Surg Med 32(4):
327–330
14. Truchuelo MT, Boixeda P, Alcántara J, Moreno C, De Las HE,
Olasolo PJ (2012) Pulsed dye laser as an excellent choice of treat-
ment for lupus tumidus: a prospective study. J Eur Acad Dermatol
Venereol 26(10):1272–1279
15. Erceg A, Bovenschen HJ, Van de Kerkhof PCM, de Jong EMJG,
Seyger MMB (2009) Efficacy and safety of pulsed dye laser
treatment for cutaneous discoid lupus erythematosus. J Am Acad
Dermatol 60(4):626–632
16. Brauer JA, Gordon Spratt EA, GeronemusRG (2013) Laser therapy
in the treatment of connective tissue diseases: a review. Dermatol
Surg 1–13
17. Bonilla-Martinez ZL, Albrecht J, Troxel AB et al (2008) The cuta-
neous lupus erythematosus disease area and severity index. Arch
Dermatol 144(2):173–180
18. Parver D, Dreher R (2012) Ocular injury after laser hair reduction
treatment to the eyebrow. Arch Opthalmol 130(10):1330–1334
19. Karabela Y, Eliacik M (2015) Anterior uveitis following eyebrow
epilation with alexandrite laser. Int Med Case Rep J 8:177–179
20. Hammes S, Augustin A, Raulin C, Ockenfels H-M, Fischer E
(2007) Pupil damage after periorbital laser treatment of a port-
wine stain. Arch Dermatol 143(3):392–394
21. Crabb M, Chan WO, Taranath D, Huilgol SC (2014) Intense
pulsed light therapy (IPL) induced iritis following treatment for
a medial canthal capillary malformation. Australas J Dermatol
55(4):289–291
22. Smalley PJ (2011) Laser safety: risks, hazards, and control mea-
sures. Laser Ther 20(2):95–106
23. Ekbäck MP, Troilius A (2013) Laser therapy for refractory discoid
lupus erythematosus when everything else has failed. J Cosmet
Laser Ther 15(5):260–265
Lasers Med Sci
